Edgewise Therapeutics Price Target has dropped to $ 35 from $ 40 at Wedbush

Wedbush Analyst Laura Chico dropped the company a price target on peripheral therapeutics (Eutx) to $ 35 from $ 40 and keeps a better performing score on the shares. Edgewise said the FDA considered Canyon's data to be inadequate to…